Melanoma: Where we are and where we go

(2019) Melanoma: Where we are and where we go. JOURNAL OF CELLULAR PHYSIOLOGY. pp. 3307-3320. ISSN 0021-9541 1097-4652 J9 - J CELL PHYSIOL

Full text not available from this repository.

Abstract

Melanoma is known as an aggressive tumor which shows an increasing incidence and poor prognosis in the metastatic phase. Hence, it seems that diagnosis and effective management (including early diagnosis, choosing of the effective therapeutic platform, caring, and training of patients for early detection) are major aspects of melanoma therapy. Early detection of melanoma is a key point for melanoma therapy. There are various diagnosis options such as assessing of biopsy, imaging techniques, and biomarkers (i.e., several proteins, polymorphism, and liquid biopsy). Among the various biomarkers, assessing circulating tumor cells, cell-free DNAs, cell-free RNAs, and microRNAs (miRNAs) have emerged as powerful diagnosis tools for melanoma patients. Deregulations of these molecules are associated with melanoma pathogenesis. After detection of melanoma, choosing of effective therapeutic regimen is a key step for recovery of melanoma patients. Several studies indicated that various therapeutic approaches including surgery, immunotherapy, systematic therapy, radiation therapy and antibodies therapy could be used as potential therapeutic candidates for melanoma therapy. Caring for melanoma patients is one of the important components of melanoma therapy. Caring and training for melanoma patients could contribute to better monitoring of patients in response to various therapeutic options. Here, we summarized various diagnosis approaches such as assessing biopsy, imaging techniques, and utilization of various biomarkers (i.e., proteins, CTCs, cfDNAs, and miRNAs) as a diagnostic biomarker for detection and monitoring patients with melanoma. Moreover, we highlighted various therapeutic options and caring aspects in patients with melanoma.

Item Type: Article
Keywords: diagnosis management melanoma therapy CUTANEOUS MALIGNANT-MELANOMA TUMOR-SUPPRESSOR GENES ADOPTIVE CELL TRANSFER METASTATIC MELANOMA EPIGENETIC INACTIVATION MOLECULAR CLASSIFICATION CIRCULATING MICRORNAS ABERRANT METHYLATION DIAGNOSTIC BIOMARKER IMPROVED SURVIVAL
Page Range: pp. 3307-3320
Journal or Publication Title: JOURNAL OF CELLULAR PHYSIOLOGY
Journal Index: ISI
Volume: 234
Number: 4
Identification Number: https://doi.org/10.1002/jcp.27286
ISSN: 0021-9541 1097-4652 J9 - J CELL PHYSIOL
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/18191

Actions (login required)

View Item View Item